Research Network for Metals in Medicine



Dr Anne Hamilton


Position: Staff Specialist (Attending Physician)

Affiliation: Sydney Cancer Centre, Royal Prince Alfred Hospital

Postal Address:
Level 6, Gloucester House
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050

Phone: +61 (2) 9515 5894
Fax: +61 (2) 9519 1546

Career Profile

Positions and Employment

1990 - 96 Melbourne, AUSTRALIA
1990 - 91 Intern, Royal Melbourne Hospital
1991 - 93 Medical Resident, Royal Melbourne Hospital / Monash Medical Centre
1993 - 94 General Medical Registrar (Fellow, Internal Medicine), Royal Melbourne Hospital
1994 - 96 Medical Oncology / Haematology Registrar (Fellow, Medical Oncology / Hematology), Royal Melbourne Hospital / Austin and Repatriation Medical Centre / Western Hospital
1996 - 98 Brussels, BELGIUM
1996 - 98 Clinical Research Fellow, European Organisation for Research and Treatment of Cancer (EORTC) / Institut Jules Bordet
1999 - 2002 New York NY, USA
1999 Research Associate, New York University Cancer Institute
1999 - 2002 Assistant Professor of Clinical Medicine, New York University Cancer Institute
2001 - 02 Attending Physician, Bellevue Hospital Center
2002 - Sydney, AUSTRALIA
2002 - Staff Specialist (Attending Physician), Sydney Cancer Centre, Royal Prince Alfred Hospital
2003 - Senior Lecturer, University of Sydney

Other Experience and Professional Memberships
1994 - Member, Medical Oncology Group of Australia (MOGA)
1999 - Member, American Society of Clinical Oncology (ASCO)
2002 - Member, Scientific Advisory Board, Australia and New Zealand Breast Cancer Trials Group
2003 - Member, Scientific Advisory Board, Australian Ovarian Cancer Study (DOD funded)

2002 Faculty of the Year Award for dedication to teaching, Division of Oncology, New York University School of Medicine

Selected Publications

  1. CH Takimoto, SC Remick, S Sharma, S Mani, RK Ramanathan, JH Doroshow, A Hamilton, D Mulkerin, M Graham, GF Lockwood, P Ivy, MJ Egorin, B Schuler, D Greenslade, A Goetz, R Knight, R Thomas, BP Monahan, W Dahut and JL Grem. A dose escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2003: 21:2664-2672
  2. R Paridaens, L Dirix, C Lohrisch, L Beex, M Nooij, D Cameron, L Biganzoli, T Cufer, L Duchateau, A Hamilton, JP Lobelle and M Piccart. Mature results of a randomized phase II multicentre study of exemestane versus tamoxifen as first line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003: 14:433-40
  3. P Therasse, L Mauriac, J Jassem, P Bruning, T Cufer, H Bonnefoi, E Tomiak, A Hamilton and M Piccart. Neoadjuvant dose intensive chemotherapy in locally advanced breast cancer. An EORTC-NCIC-SAKK randomized phase III study comparing FEC (5-FU, epirubicin, cyclophosphamide) vs high-dose intensive EC+G-CSF (Filgrastim). J Clin Oncol 2003; 21:843-50
  4. H Bonnefoi, S Diebold-Berger, P Therasse, A Hamilton, M van de Vijver, G Mac Grogan, L Shepherd, N Amaral, C Duval, R Drijkoningen, D Larsimont and M Piccart. Locally advanced / inflammatory breast cancers treated with intensive epirubicin based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5 year clinical outcome? Ann Oncol 2003; 14:406-13
  5. S Sewak, A Chachoua, A Hamilton, S Taneja, J Lee, M Utate, J Sorich and FM Muggia. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (pacl-e-vin) in advanced malignancies: triple tubulin targeting. Anti-Cancer Drugs 2003;14: 67-72
  6. L Biganzoli, T Cufer, P Bruning, RE Coleman, L Duchateau, B Rapoport, M Nooij, F Delhaye, P Ellis, A Sulkes, A Hamilton, and M Piccart. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast cancer patients. Results from an EORTC multicenter trial. Cancer 2003;97:40-45
  7. A Hamilton. Ethical issues surrounding the conduct of off-shore clinical research. J Clin Oncol 2002;20(18): 3934 (letter).
  8. FM Muggia, L Liebes, M Hazarika, S Wadler, A Hamilton, G Hornreich, J Sorich, C Chiang, E Newman, M Potmesil and H Hochster. Phase I and pharmacologic study of intraperitoneal 9-aminocamptothecin given as six fractions over 14 days. Anti-Cancer Drugs 2002;13:819-25
  9. A Hamilton, L Biganzoli, R Coleman, L Mauriac, P Hennebert, A Awada, M Nooij, L Beex, M Piccart, I Van Hoorebeeck, D de Valeriola and P Bruning. EORTC 10968: A phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a six-week interval in patients with metastatic breast cancer. Ann Oncol 2002;13:910-18
  10. A Awada, L Biganzoli, T Cufer, L Beex, C Lohrisch, V Batter, A Hamilton, M Nooij and M Piccart. An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. Eur J Cancer 2002;38(6):773-8
  11. H Bonnefoi, L Biganzoli, T Cufer, L Mauriac, A Hamilton, P Schaefer, M Piccart. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-FU (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Breast Ca Res Treat 2001;70(1):55-63
  12. F Muggia and A Hamilton. Phase III data on Caelyx® in ovarian cancer. Eur J Cancer 2001; 37 (Suppl 9):S15-18
  13. A Hamilton and M Volm. Steroidal and non-steroidal aromatase inhibitors in breast cancer. Oncology (Huntington) 2001;15(8):965-972
  14. A Hamilton and F Muggia. Estramustine potentiates taxane in prostate and refractory breast cancers. Oncology (Huntington) 2001; 15(5, Supp 7):40-43
  15. F Muggia, L Liebes, M Potmesil, A Hamilton, H Hochster, G Hornreich, J Sorich, A Downey and H Wasserstrom. Intraperitoneal topoisomerase-1 inhibitors: preliminary findings with 9-aminocamptothecin. Ann NY Acad Sci 2000: 922:178-87
  16. A Hamilton, D Larsimont, R Paridaens, M Drijkonongen, M van de Vijver, P Bruning, A Hanby, S Houston, I Treilleux, J-P Guastalla, A Van Vreckem, R Sylvester and M Piccart. A study of the value of p53, HER-2 and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer; a companion study to EORTC 10923. Clinical Breast Cancer 2000;1(3):233-240
  17. A Hamilton, J-A Roy, L Beex, M Piccart, L Mauriac, R Paridaens, G Hoctin Boes, A Van Vreckem, P Palmer and J Klijn. EORTC 10941: A phase H study of liarozole in postmenopausal patients with "chemotherapy-resistant" or "potentially hormone-sensitive" metastatic breast cancer. Br Cancer Res Treat 2000;60(2):181-188
  18. A Hamilton and M Piccart. The contribution of molecular markers to the prediction of response in the treatment of breast cancer; a review of the literature on HER-2, p53 and Bcl-2. Ann Oncol 2000; 11(6):647-663
  19. M Piccart, A Di Leo and A Hamilton. HER-2: a predictive factor ready to use in the daily management of breast cancer patients. Eur J Cancer 2000;36(14):1755-61
  20. FM Muggia and A Hamilton. Modulation of taxanes in breast cancer. Cancer Investigation 2000;18(Suppl 1):64-66
  21. A Hamilton and M Piccart. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line treatment of advanced breast cancer. Ann Oncol 1999;10(4):377-384
  22. JJ Rusthoven, EGE de Vries, DC Dale, M Piccart, J Glaspy and A Hamilton. Consensus on the use of neutrophil-stimulating hemopoietic growth factors in clinical practice: an international viewpoint. Int J Antimicrobial Agents 1997;8:263-275